ATE419375T1 - Amplifizierung von cyp24 und anwendung dafür - Google Patents

Amplifizierung von cyp24 und anwendung dafür

Info

Publication number
ATE419375T1
ATE419375T1 AT00916145T AT00916145T ATE419375T1 AT E419375 T1 ATE419375 T1 AT E419375T1 AT 00916145 T AT00916145 T AT 00916145T AT 00916145 T AT00916145 T AT 00916145T AT E419375 T1 ATE419375 T1 AT E419375T1
Authority
AT
Austria
Prior art keywords
cyp24
level
cancer
animal
biological sample
Prior art date
Application number
AT00916145T
Other languages
English (en)
Inventor
Donna Albertson
Daniel Pinkel
Colin Collins
Joe Gray
Bauke Ystra
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE419375T1 publication Critical patent/ATE419375T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00916145T 1999-04-02 2000-03-06 Amplifizierung von cyp24 und anwendung dafür ATE419375T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/285,292 US7648826B1 (en) 1999-04-02 1999-04-02 Detecting CYP24 expression level as a marker for predisposition to cancer

Publications (1)

Publication Number Publication Date
ATE419375T1 true ATE419375T1 (de) 2009-01-15

Family

ID=23093617

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916145T ATE419375T1 (de) 1999-04-02 2000-03-06 Amplifizierung von cyp24 und anwendung dafür

Country Status (7)

Country Link
US (4) US7648826B1 (de)
EP (1) EP1255850B1 (de)
JP (1) JP4790127B2 (de)
AT (1) ATE419375T1 (de)
CA (1) CA2367291C (de)
DE (1) DE60041278D1 (de)
WO (1) WO2000060109A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7648826B1 (en) * 1999-04-02 2010-01-19 The Regents Of The University Of California Detecting CYP24 expression level as a marker for predisposition to cancer
JP2005500832A (ja) * 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド 乳癌患者の診断および予後
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
SI3095447T1 (sl) 2006-02-03 2022-02-28 Opko Renal, Llc Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3
HUE037309T2 (hu) 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
PL2148661T3 (pl) 2007-04-25 2013-07-31 Cytochroma Inc Doustne kompozycje o kontrolowanym uwalnianiu zawierające związek będący witaminą D i woskowy nośnik
DK2148684T3 (da) 2007-04-25 2013-04-22 Cytochroma Inc Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
US9670551B2 (en) 2007-11-30 2017-06-06 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9797017B2 (en) 2007-11-30 2017-10-24 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9783857B2 (en) 2007-11-30 2017-10-10 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US10113203B2 (en) 2007-11-30 2018-10-30 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9670552B2 (en) 2007-11-30 2017-06-06 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
CN102912019B (zh) 2007-11-30 2016-03-23 基因特力株式会社 使用膀胱癌特异性甲基化标记基因的膀胱癌诊断试剂盒和芯片
CN102046812A (zh) * 2008-04-02 2011-05-04 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
US8614071B2 (en) * 2009-12-11 2013-12-24 Roche Molecular Systems, Inc. Preferential amplification of mRNA over DNA using chemically modified primers
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
US9135694B2 (en) 2012-12-04 2015-09-15 General Electric Company Systems and methods for using an immunostaining mask to selectively refine ISH analysis results
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
MY198547A (en) 2016-03-28 2023-09-04 Opko Ireland Global Holdings Ltd Methods of vitamin d treatment
CN113267529B (zh) * 2021-05-12 2022-10-25 江西师范大学 一种温度型生物传感器及利用温度型生物传感器检测目标适体的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6808878B1 (en) 1996-07-15 2004-10-26 The Regents Of The University Of California Genes from the 20Q13 amplicon and their uses
US7648826B1 (en) 1999-04-02 2010-01-19 The Regents Of The University Of California Detecting CYP24 expression level as a marker for predisposition to cancer
US7427670B2 (en) * 2003-12-19 2008-09-23 Cytochroma Inc. Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof

Also Published As

Publication number Publication date
WO2000060109A1 (en) 2000-10-12
EP1255850A4 (de) 2005-02-09
EP1255850B1 (de) 2008-12-31
US8685929B2 (en) 2014-04-01
US20100285023A1 (en) 2010-11-11
US8173602B2 (en) 2012-05-08
JP2002540798A (ja) 2002-12-03
US20120322674A1 (en) 2012-12-20
US20140187441A1 (en) 2014-07-03
CA2367291C (en) 2012-05-15
US7648826B1 (en) 2010-01-19
DE60041278D1 (de) 2009-02-12
CA2367291A1 (en) 2000-10-12
JP4790127B2 (ja) 2011-10-12
EP1255850A1 (de) 2002-11-13

Similar Documents

Publication Publication Date Title
ATE419375T1 (de) Amplifizierung von cyp24 und anwendung dafür
Liu et al. Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
Hagemann et al. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-α dependent up-regulation of matrix metalloproteases
Moretti et al. β-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
Zhang et al. A lymph node metastatic mouse model reveals alterations of metastasis‐related gene expression in metastatic human oral carcinoma sublines selected from a poorly metastatic parental cell line
Okada Beyond foreign‐body‐induced carcinogenesis: impact of reactive oxygen species derived from inflammatory cells in tumorigenic conversion and tumor progression
DE60238132D1 (de) Patientenklassifizierung
Aguado et al. Biomaterial scaffolds as pre‐metastatic niche mimics systemically alter the primary tumor and tumor microenvironment
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
ATE529535T1 (de) Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
ATE406575T1 (de) Verfahren zur erkennung von medikamentenempfindlichkeit in patienten mit entzündungskrankheiten
ATE485366T1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
Pannier et al. High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
WO2002090925A3 (en) Polypeptides and nucleic acids associated with cancer
WO2002077197A3 (en) Methods for diagnosing and monitoring malignancies by screening gene copy numbers
ATE466938T1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
Al Moustafa et al. Up-regulation of E-cadherin by an anti-epidermal growth factor receptor monoclonal antibody in lung cancer cell lines
Ota et al. Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
ATE256120T1 (de) Reagentien für cyp2d fluoreszenztest
DE69636041D1 (de) Nachweis von brusttumorvirus-artigen sequenzen in brustkrebs bei menschen
WO2003021225A3 (en) Method for classification of anti-psychotic drugs
ATE434044T1 (de) Antikörper gegen tumorspezifisches antigen als ziel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties